Observational studyBMC cardiovascular disorders2026
Prognostic value of serum gasdermin D in predicting major adverse cardiovascular events in patients with unstable angina: a prospective observational study.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study investigated the prognostic significance of serum gasdermin D (GSDMD) in unstable angina (UA) and its association with inflammatory cytokines, myocardial injury markers, and 1-year major adverse cardiovascular events (MACE).
methodsA total of 221 UA patients were prospectively enrolled and followed for 12 months. Serum levels of GSDMD, IL-6, IL-1β, TNF-α, and CRP were measured by ELISA. NT-proBNP, CK-MB, and cTnI were quantified using automated immunoassays. Patients were stratified by 1-year MACE outcomes.
resultsSerum GSDMD, IL-6, and IL-1β were significantly higher in the MACE group (all p < 0.01), while TNF-α and CRP showed no differences. GSDMD levels correlated with IL-6 and NT-proBNP (p < 0.001). ROC analysis showed GSDMD predicted MACE with an AUC of 0.800 (95% CI: 0.741–0.859, p < 0.001). Logistic regression identified serum GSDMD levels (OR = 2.601, 95% CI: 1.652–3.701, p < 0.001) and NT-proBNP (OR = 1.055, 95% CI: 1.030–1.080, p < 0.001) as independent predictors of MACE.
conclusionElevated GSDMD was associated with adverse outcomes in UA and served as an independent prognostic biomarker, suggesting a potential role of pyroptosis-related inflammation in acute coronary syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.